Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Int J Tuberc Lung Dis. 2001 Dec;5(12):1078-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Government Programs / trends*
  • Humans
  • International Cooperation
  • Isoniazid / therapeutic use*
  • National Health Programs / trends*
  • Practice Guidelines as Topic
  • Rifampin / therapeutic use*
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • World Health Organization

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin